Compare Aurobindo Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA FRESENIUS KABI ONCO. AUROBINDO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 19.7 22.1 89.1% View Chart
P/BV x 4.3 3.1 137.0% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 AUROBINDO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
AUROBINDO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs830176 471.6%   
Low Rs52779 671.5%   
Sales per share (Unadj.) Rs333.937.7 886.0%  
Earnings per share (Unadj.) Rs40.45.1 792.3%  
Cash flow per share (Unadj.) Rs51.86.7 769.8%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.142.5 557.3%  
Shares outstanding (eoy) m585.91158.23 370.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.4 60.2%   
Avg P/E ratio x16.825.0 67.3%  
P/CF ratio (eoy) x13.118.9 69.3%  
Price / Book Value ratio x2.93.0 95.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,56920,135 1,974.5%   
No. of employees `00017.91.2 1,549.9%   
Total wages/salary Rs m25,849703 3,675.9%   
Avg. sales/employee Rs Th10,956.95,176.2 211.7%   
Avg. wages/employee Rs Th1,447.7610.4 237.2%   
Avg. net profit/employee Rs Th1,324.3699.6 189.3%   
INCOME DATA
Net Sales Rs m195,6365,963 3,280.8%  
Other income Rs m1,55318 8,628.9%   
Total revenues Rs m197,1895,981 3,296.9%   
Gross profit Rs m39,5191,430 2,763.4%  
Depreciation Rs m6,680258 2,590.0%   
Interest Rs m2,626-26 -10,100.0%   
Profit before tax Rs m31,7671,216 2,612.0%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-68 1,293.1%   
Tax Rs m7,269342 2,124.1%   
Profit after tax Rs m23,645806 2,934.0%  
Gross profit margin %20.224.0 84.2%  
Effective tax rate %22.928.1 81.3%   
Net profit margin %12.113.5 89.4%  
BALANCE SHEET DATA
Current assets Rs m153,6455,102 3,011.7%   
Current liabilities Rs m120,4292,385 5,048.6%   
Net working cap to sales %17.045.6 37.3%  
Current ratio x1.32.1 59.7%  
Inventory Days Days135150 90.1%  
Debtors Days Days64113 56.2%  
Net fixed assets Rs m103,9095,148 2,018.4%   
Share capital Rs m586158 370.4%   
"Free" reserves Rs m138,3226,556 2,110.0%   
Net worth Rs m138,9086,732 2,063.5%   
Long term debt Rs m1,800952 189.0%   
Total assets Rs m264,54410,388 2,546.6%  
Interest coverage x13.1-45.8 -28.6%   
Debt to equity ratio x00.1 9.2%  
Sales to assets ratio x0.70.6 128.8%   
Return on assets %9.97.5 132.3%  
Return on equity %17.012.0 142.2%  
Return on capital %23.814.6 163.2%  
Exports to sales %49.674.5 66.6%   
Imports to sales %18.824.8 75.8%   
Exports (fob) Rs m97,0914,441 2,186.4%   
Imports (cif) Rs m36,7411,477 2,486.9%   
Fx inflow Rs m97,3165,298 1,837.0%   
Fx outflow Rs m40,5891,772 2,290.3%   
Net fx Rs m56,7273,525 1,609.1%   
CASH FLOW
From Operations Rs m16,2201,274 1,273.1%  
From Investments Rs m-28,768-1,204 2,389.0%  
From Financial Activity Rs m19,191-196 -9,786.1%  
Net Cashflow Rs m6,656-126 -5,270.3%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 8.0 0.3 2,650.0%  
FIIs % 27.7 9.6 288.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 9.1 112.1%  
Shareholders   69,601 42,599 163.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ABBOTT INDIA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS